Alessandro Preti
- Clinical Biochemistry top 1%
- Immunology top 10%
- Molecular Biology
- Neurology top 10%
- Oncology
- Co-authors
- Marco E. BianchiFrancesco De MarchisMaura CasalgrandiEmilie VénéreauJaron LiuMariagrazia UguccioniLuca VaraniAngela Cattaneo
- Topics
- Advanced Glycation End Products research (6 papers)S100 Proteins and Annexins (4 papers)Neutrophil, Myeloperoxidase and Oxidative Mechanisms (2 papers)
- Journals
- The Journal of Experimental MedicineFrontiers in ImmunologyThe Journal of General Physiology
- Partner nations
- ItalyUnited StatesSweden
In The Last Decade
Alessandro Preti
9 papers receiving 718 citations
Hit Papers
Peers
Comparison fields: 5 of 78
- Clinical Biochemistry 380
- Immunology 323
- Molecular Biology 227
- Neurology 76
- Oncology 67
Countries citing papers authored by Alessandro Preti
This map shows the geographic impact of Alessandro Preti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alessandro Preti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alessandro Preti more than expected).
Fields of papers citing papers by Alessandro Preti
This network shows the impact of papers produced by Alessandro Preti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alessandro Preti. The network helps show where Alessandro Preti may publish in the future.
Co-authorship network of co-authors of Alessandro Preti
This figure shows the co-authorship network connecting the top 25 collaborators of Alessandro Preti. A scholar is included among the top collaborators of Alessandro Preti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alessandro Preti. Alessandro Preti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 0 | |
| 2 | 35 | |
| 3 | 36 | |
| 4 | 58 | |
| 5 | Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine releasebreakdown → | 561 |
| 6 | 4 | |
| 7 | 8 | |
| 8 | 4 | |
| 9 | CRF antagonists Dupont. | 3 |
| 10 | BP-897 Bioprojet. | 12 |
About Alessandro Preti
Alessandro Preti is a scholar working on Clinical Biochemistry, Immunology and Obstetrics and Gynecology, having authored 10 papers that have together received 721 indexed citations. Recurring topics across this work include Advanced Glycation End Products research (6 papers), S100 Proteins and Annexins (4 papers) and Neutrophil, Myeloperoxidase and Oxidative Mechanisms (2 papers). The work is most often cited by research in Clinical Biochemistry (380 citations), Immunology (323 citations) and Neurology (76 citations). Alessandro Preti has collaborated with scholars based in Italy, United States and Sweden. Frequent co-authors include Marco E. Bianchi, Francesco De Marchis, Maura Casalgrandi, Emilie Vénéreau, Jaron Liu, Mariagrazia Uguccioni, Luca Varani, Angela Cattaneo, Huan Yang and Angela Bachi. Their work appears in journals such as The Journal of Experimental Medicine, Frontiers in Immunology and The Journal of General Physiology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.